Low-Dose Topiramate in Alcohol Dependence: A Single-Blind, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Topiramate (TOP) and anticonvulsants in general are considered safe and effective drugs for the treatment of alcohol dependence, even though TOP-induced adverse events are quite common, especially for high initial doses or if titration to 300 mg/d is too rapid. The aim of the present study was to assess the efficacy and tolerability profile of low-dose TOP for relapse prevention. METHODS: After detoxification, 52 patients were randomized into 2 groups as follows: 26 patients received 100 mg of TOP (oral, twice daily), titrated over 2 weeks, and 26 patients received placebo (PLA). Both groups underwent rehabilitation twice a week. RESULTS: After 6 weeks of treatment, compared with the PLA group, patients receiving TOP showed the following: (1) fewer drinking days (P < 0.05); (2) less daily alcohol consumption (P < 0.05); (3) more days of treatment (P < 0.05); (4) reduced levels of craving (Obsessive-Compulsive Drinking Scale) and withdrawal symptoms (Clinical Institute Withdrawal Assessment for Alcohol-Revised); and (5) improvement of anxiety, depression, and obsessive-compulsive symptom severity (Symptom Check List 90 Revised). CONCLUSIONS: Despite the small sample size and the short follow-up period, the present PLA-controlled study demonstrated the potential usefulness of TOP, even when administered at a dosage of 100 mg/d, for the treatment of detoxified alcohol-dependent subjects, confirming results from previous studies testing higher doses of TOP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
The epidemiology of dual diagnosis
Kessler, R. C. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.034 · Cited by 588 · cited 1×
“Moreover, the efficacy of some anticonvulsants in treating psychiatric symptoms in substance use disorder patients is also relevant, given the high number of alcohol-dependent subjects presenting a dual diagnosis.(13) Topiramate, a sulfamate-substituted analogous of fructose1,6-diphosphate, is a potent antiepileptic(1…”
BackgroundTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Comparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Reduction in heavy drinking as a treatment outcome in alcohol dependence
Gastfriend, D. R., Garbutt, J. C., Pettinati, H. M., & Forman, R. F. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.09.008 · Cited by 139 · cited 1×
“This definition has been referred to for research purposes in different studies.(33,34) Secondary study end points included the number of abstinent days, average daily alcohol consumption, retention in treatment, and reduction of alcohol craving.”
BackgroundLikhitsathian, S., Uttawichai, K., Booncharoen, H., Wittayanookulluk, A., Angkurawaranon, C., & Srisurapanont, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.06.032 · Cited by 46
Cited by
Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171
Self-citationNourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
“3 Percentage of Abstinent Days Five double-blind RCTs comparing topiramate against placebo [16–18, 21, 23], one single-blind RCT comparing topiramate against placebo [31] and one unblinded RCT comparing topiramate against cognitive behavioral therapy (CBT) [28] found a significant improvement in this parameter.”
BackgroundResultInfluentialA Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder
Fluyau, D., Kailasam, V. K., & Pierre, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221149643 · Cited by 20
“…et al., 2008; Batki et al., 2014; Johnson et al., 2003, 2007; Kampman et al., 2013; Knapp et al., 2015; Kranzler et al., 2014; Likhitsathian et al., 2013; Martinotti et al., 2014; Pennington et al., 2020; Rubio et al., 2009; Sylvia et al., 2016) were considered for the quantitative analysis.”
BackgroundMethodGray, J. C., Treloar Padovano, H., Wemm, S. E., & Miranda, R. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000843 · Cited by 18
Metadata
- Authors
- Martinotti, G., Di Nicola, M., De Vita, O., Hatzigiakoumis, D. S., Guglielmo, R., Santucci, B., Aliotta, F., Romanelli, R., Verrastro, V., Petruccelli, F., Di Giannantonio, M., & Janiri, L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2014-12
- Volume
- 34
- Issue
- 6
- Pages
- 709-715
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1967507587
- Cited by
- 48
- References
- 8
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Topiramate in Alcohol Dependence: A Single-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/jcp.0000000000000228
- The paper
- Martinotti, G., Di Nicola, M., De Vita, O., Hatzigiakoumis, D. S., Guglielmo, R., Santucci, B., Aliotta, F., Romanelli, R., Verrastro, V., Petruccelli, F., Di Giannantonio, M., & Janiri, L. (2014). Low-Dose Topiramate in Alcohol Dependence: A Single-Blind, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000228
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.